Shire Pharmaceuticals
About Shire Pharmaceuticals
There’s a simple purpose that sits at the heart of our business: to enable people with life-altering conditions to lead better lives. This means we focus on developing treatments for conditions where the impact of our medicines can make an immediate and tangible difference for patients.
Our growth strategy is to focus on developing and marketing innovative specialty medicines for symptomatic conditions to meet significant unmet patient needs. Our two strategic priorities are to drive optimum performance of our existing products, enabling access to these medicines for patients today; and building our pipeline through research and development (R&D) and business development (BD), delivering access in the future for patients We are always looking for talented people to join the Shire team.
To learn more about Shire, visit www.shire.com.
For more information on career opportunities with Shire, please visit: www.TimeToBeBrave.com .
Shire. To be as brave as the people we help.
367 articles about Shire Pharmaceuticals
-
Ethris Announces Research Based Alliance on SNIM® Modified RNA With Shire plc
1/7/2013
-
Shire plc ADHD Drug Elvanse Close to Europe Approval
12/19/2012
-
Shire plc and Children's Hospital Boston Enter Into Broad Research Collaboration
11/20/2012
-
Shire plc Leads New Initiative to Reveal Challenges Facing Rare Disease Community
11/19/2012
-
Shire Pharmaceuticals Announces Third Annual Scholarship Program for Individuals With ADHD
11/6/2012
-
Shire Pharmaceuticals Hunts More Deals Amid Reawakening Interest in Stem Cell R&D
10/29/2012
-
Shire Pharmaceuticals Release: International Study Reveals Disconnect Between Patients and Healthcare Professionals (HCPS) Over Symptom Burden in Ulcerative Colitis (UC)
10/22/2012
-
Albany Molecular Research, Inc. (AMRI) Announces Five-Year Extension of API Supply Agreement With Shire
10/19/2012
-
Frederic Chereau Joins Shire Human Genetic Therapies to Lead Angioedema Franchise
9/26/2012
-
Shire Pharmaceuticals Announces FDA Acceptance of Filing for Review of the Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) sNDA for Maintenance Treatment in Children and Adolescents With ADHD European Medicines Agency
9/12/2012
-
Shire plc Second Quarter Product Sales Up 16%
8/1/2012
-
Shire plc Release: Second Quarter 2012 Results Date Notification - August 1, 2012
7/19/2012
-
Shire plc Hit as US Approves New Generic ADHD Drug
6/25/2012
-
Shire plc Release: Professional Baseball Player Shane Victorino Raises Awareness of Attention-Deficit/Hyperactivity Disorder in Young Adults and Adults Through "Own It" Initiative
5/22/2012
-
Shire plc Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5/15/2012
-
Promedior Moves Fibrosis Pipeline to Boston, Hires Shire plc Vet as CEO
5/15/2012
-
Shire plc to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
5/4/2012
-
Shire plc Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
4/26/2012
-
Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4/13/2012
-
Massachusetts Sees $2 Billion Construction Boom from the Biopharma Industry Including Shire Human Genetic Therapies and Pfizer Inc.
4/6/2012